Alectinib will be administrated under fast conditions.
The primary endpoint of the phase II part was ORR. Other secondary endpoints in phase II are
progression-free survival (PFS), overall survival (OS), intracranial response (ICR), and
duration of response (DOR).
Exploratory endpoints in this follow-up analysis included the evaluation of the correlation
between tumor shrinkage and PFS and chosen dose to relieve cancer symptoms.
